HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Martek acquisition

This article was originally published in The Tan Sheet

Executive Summary

Columbia, Md.-based firm completes purchase of FermPro Manufacturing and its Kingstree, S.C. plant. Transaction is expected to add at least $30 to $50 mil. of production capacity for Martek after operations and equipment are fully integrated (1"The Tan Sheet" July 28, 2003, p. 14). Martek also is in the process of spending $20 mil. to $30 mil. to increase manufacturing capacity of its Winchester, Ky. facility (2"The Tan Sheet" June 9, 2003, p. 9). Firm appoints FermPro President & CEO Barney Easterling as Martek VP...

You may also be interested in...



Martek increases credit

Columbia, Md.-based firm announces entry into $85 mil. revolving credit facility Jan. 27. Manufacturing & Traders Trust Company, Bank of America and SunTrust Bank will serve as administrative agent and sole book runner, syndication agent and documentation agent, respectively, for the new revolving credit facility, which replaces Martek's previous $10 mil. revolving credit line, which was set to expire in February. "The increase in the credit facility reflects our growing financial strength and is an important element in our financial plan to support ongoing expansion of our manufacturing facilities," Chairman & CEO Henry Linsert says (1"The Tan Sheet" Sept. 15, 2003, In Brief)...

Business In Brief

Pfizer: Consumer Healthcare sales of $741 mil., up 14%, in the second quarter, were driven by the continued strong performance of Listerine mouthwash and uptake of Listerine PocketPaks in international markets. The rollout of FreshBurst Listerine line extensions and the weaker dollar also helped edge up revenues. Sales of PocketPaks in the U.S. slowed and the firm's Benadryl and Sudafed line were hurt by the presence of OTC Claritin on the market, Pfizer notes...

Martek Production Capacity Expected To Reach $200 Mil.-$250 Mil. in 2004

Martek plans to spend between $20 mil. and $30 mil. over the next 12 months on increasing its fermentation capacity, the Columbia, Md.-based firm said during a June 3 analysts call

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129847

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel